4D Pharma, plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From 4D Pharma, plc
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
There is growing interest in the gut microbiome as a source of new therapies across a wide range of diseases. Although it is still an emerging field, pharmaceutical firms and other investors are engaging, with more expected to follow.
Adversity has honed a solid foundation for U.K. biotech that might be better placed to resist cyclical changes in investor sentiment than the U.S., proposes the head of the U.K biotech industry association.
European biotech companies that have lead products turned down by big pharma are now considering the benefits of taking drugs through late-stage development themselves; more funding options, such as concluding an IPO in the U.S. or Europe, is driving some of this change.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Life Sciences Innovation
- GT Biologics
- Longevity Acquisition Corporation